Search

Replisome disassembly is the final step of eukaryotic DNA replication and is triggered by ubiquitylation of the CDC45-MCM-GINS (CMG) replicative helicase.sup.1-3. Despite being driven by evolutionarily diverse E3 ubiquitin ligases in different eukaryotes (SCF.sup.Dia2 in budding yeast.sup.1, CUL2.sup.LRR1 in metazoa.sup.4-7), replisome disassembly is governed by a common regulatory principle, in which ubiquitylation of CMG is suppressed before replication termination, to prevent replication fork collapse. Recent evidence suggests that this suppression is mediated by replication fork DNA.sup.8-10. However, it is unknown how SCF.sup.Dia2 and CUL2.sup.LRR1 discriminate terminated from elongating replisomes, to selectively ubiquitylate CMG only after termination. Here we used cryo-electron microscopy to solve high-resolution structures of budding yeast and human replisome-E3 ligase assemblies. Our structures show that the leucine-rich repeat domains of Dia2 and LRR1 are structurally distinct, but bind to a common site on CMG, including the MCM3 and MCM5 zinc-finger domains. The LRR-MCM interaction is essential for replisome disassembly and, crucially, is occluded by the excluded DNA strand at replication forks, establishing the structural basis for the suppression of CMG ubiquitylation before termination. Our results elucidate a conserved mechanism for the regulation of replisome disassembly in eukaryotes, and reveal a previously unanticipated role for DNA in preserving replisome integrity. A conserved mechanism for the regulation of replisome disassembly in eukaryotes is shown using cryo-electron microscopy, revealing a role for DNA in the preservation of replisome integrity., Author(s): Michael Jenkyn-Bedford [sup.1] , Morgan L. Jones [sup.1] , Yasemin Baris [sup.1] , Karim P. M. Labib [sup.2] , Giuseppe Cannone [sup.1] , Joseph T. P. Yeeles [sup.1] , [...]

DONSON is one of 13 genes mutated in a form of primordial microcephalic dwarfism known as Meier‐Gorlin syndrome. The other 12 encode components of the CDC45‐MCM‐GINS helicase, around which the eukaryotic replisome forms, or are factors required for helicase assembly during DNA replication initiation. A role for DONSON in CDC45‐MCM‐GINS assembly was unanticipated, since DNA replication initiation can be reconstituted in vitro with purified proteins from budding yeast, which lacks DONSON. Using mouse embryonic stem cells as a model for the mammalian helicase, we show that DONSON binds directly but transiently to CDC45‐MCM‐GINS during S‐phase and is essential for chromosome duplication. Rapid depletion of DONSON leads to the disappearance of the CDC45‐MCM‐GINS helicase from S‐phase cells and our data indicate that DONSON is dispensable for loading of the MCM2‐7 helicase core onto chromatin during G1‐phase, but instead is essential for CDC45‐MCM‐GINS assembly during S‐phase. These data identify DONSON as a missing link in our understanding of mammalian chromosome duplication and provide a molecular explanation for why mutations in human DONSON are associated with Meier‐Gorlin syndrome. Synopsis: DONSON is required for assembly of the CMG helicase in mammalian cells. This explains why hypomorphic mutations in human DONSON cause Meier‐Gorlin Syndrome, which is associated with defects in CMG helicase assembly or function. DONSON binds directly to the CMG helicase but is not a stable component of the replisome.DONSON is essential for DNA replication in mouse embryonic stem cells.DONSON is essential for assembly of the CMG helicase.DONSON is dispensable for loading of the MCM2‐7 helicase core but is required for stable association of GINS and CDC45 with loaded MCM2‐7. [ABSTRACT FROM AUTHOR]

Patients and methods: This was a prospective double-blinded multi-center randomized controlled trial conducted from April 2022 till September 2022 involving one hundred eighty women categorized into three categories, each involving 60 females who received either tranexamic acid, etamsylate or placebo just after birth of the baby. Results: Loss of blood in tranexamic acid was the same as the blood loss in etamsylate and both wer e lower than the placebo group. The difference in hemoglobin after delivery in tranexamic acid individuals was the same as etamsylate group and both of them were lower than placebo group. The occurrence of postpartum hemorrhage and blood transfusion in tranexamic acid category and etamsylate category were significantly less than placebo. Conclusions: Etamsylate is an efficiently alternative agent for tranexamic acid in decreasing blood loss with lower side effects, therefore, it can be used instead of tranexamic acid in women with contraindications or anticipated to be have higher risk to develop tranexamic acid side effects. [ABSTRACT FROM AUTHOR]

Efficient duplication of the genome requires the concerted action of helicase and DNA polymerases at replication forks (1) to avoid stalling of the replication machinery and consequent genomic instability (2-4). [...]

A method is described for inducing prolonged pausing of forks at protein barriers assembled at unique sites on a yeast chromosome, to examine for the first time the effects of pausing upon replisome integrity. The result shows that paused and stalled eukaryotic replisomes resemble each other but are regulated differently.

Author(s): Masato Kanemaki [1]; Alberto Sanchez-Diaz [1]; Agnieszka Gambus; Karim Labib (corresponding author) Analysing the role of eukaryotic proteins that are essential for cell viability requires a method by which [...]

Cullin ubiquitin ligases drive replisome disassembly during DNA replication termination. In worm, frog and mouse cells, CUL2LRR1 is required to ubiquitylate the MCM7 subunit of the CMG helicase. Here, we show that cullin ligases also drive CMG-MCM7 ubiquitylation in human cells, thereby making the helicase into a substrate for the p97 unfoldase. Using purified human proteins, including a panel of E2 ubiquitin-conjugating enzymes, we have reconstituted CMG helicase ubiquitylation, dependent upon neddylated CUL2LRR1. The reaction is highly specific to CMG-MCM7 and requires the LRR1 substrate targeting subunit, since replacement of LRR1 with the alternative CUL2 adaptor VHL switches ubiquitylation from CMG-MCM7 to HIF1. CUL2LRR1 firstly drives monoubiquitylation of CMG-MCM7 by the UBE2D class of E2 enzymes. Subsequently, CUL2LRR1 activates UBE2R1/R2 or UBE2G1/G2 to extend a single K48-linked ubiquitin chain on CMGMCM7. Thereby, CUL2LRR1 converts CMG into a substrate for p97, which disassembles the ubiquitylated helicase during DNA replication termination. [ABSTRACT FROM AUTHOR]

The COVID-19 pandemic has emerged as the biggest life-threatening disease of this century. Whilst vaccination should provide a long-term solution, this is pitted against the constant threat of mutations in the virus rendering the current vaccines less effective. Consequently, small molecule antiviral agents would be extremely useful to complement the vaccination program. The causative agent of COVID-19 is a novel coronavirus, SARS-CoV-2, which encodes at least nine enzymatic activities that all have drug targeting potential. The papain-like protease (PLpro) contained in the nsp3 protein generates viral non-structural proteins from a polyprotein precursor, and cleaves ubiquitin and ISG protein conjugates. Here we describe the expression and purification of PLpro. We developed a protease assay that was used to screen a custom compound library from which we identified dihydrotanshinone I and Ro 08-2750 as compounds that inhibit PLpro in protease and isopeptidase assays and also inhibit viral replication in cell culture-based assays. [ABSTRACT FROM AUTHOR]

The COVID-19 pandemic has presented itself as one of the most critical public health challenges of the century, with SARS-CoV-2 being the third member of the Coronaviridae family to cause a fatal disease in humans. There is currently only one antiviral compound, remdesivir, that can be used for the treatment of COVID-19. To identify additional potential therapeutics, we investigated the enzymatic proteins encoded in the SARS-CoV-2 genome. In this study, we focussed on the viral RNA cap methyltransferases, which play key roles in enabling viral protein translation and facilitating viral escape from the immune system. We expressed and purified both the guanine-N7 methyltransferase nsp14, and the nsp16 20 -O-methyltransferase with its activating cofactor, nsp10. We performed an in vitro high-throughput screen for inhibitors of nsp14 using a custom compound library of over 5000 pharmaceutical compounds that have previously been characterised in either clinical or basic research. We identified four compounds as potential inhibitors of nsp14, all of which also showed antiviral capacity in a cell-based model of SARS-CoV-2 infection. Three of the four compounds also exhibited synergistic effects on viral replication with remdesivir. [ABSTRACT FROM AUTHOR]

SARS-CoV-2 is responsible for COVID-19, a human disease that has caused over 2 million deaths, stretched health systems to near-breaking point and endangered economies of countries and families around the world. Antiviral treatments to combat COVID19 are currently lacking. Remdesivir, the only antiviral drug approved for the treatment of COVID-19, can affect disease severity, but better treatments are needed. SARS-CoV-2 encodes 16 non-structural proteins (nsp) that possess different enzymatic activities with important roles in viral genome replication, transcription and host immune evasion. One key aspect of host immune evasion is performed by the uridine-directed endoribonuclease activity of nsp15. Here we describe the expression and purification of nsp15 recombinant protein. We have developed biochemical assays to follow its activity, and we have found evidence for allosteric behaviour. We screened a custom chemical library of over 5000 compounds to identify nsp15 endoribonuclease inhibitors, and we identified and validated NSC95397 as an inhibitor of nsp15 endoribonuclease in vitro. Although NSC95397 did not inhibit SARS-CoV-2 growth in VERO E6 cells, further studies will be required to determine the effect of nsp15 inhibition on host immune evasion. [ABSTRACT FROM AUTHOR]

SARS-CoV-2 is a coronavirus that emerged in 2019 and rapidly spread across the world causing a deadly pandemic with tremendous social and economic costs. Healthcare systems worldwide are under great pressure, and there is an urgent need for effective antiviral treatments. The only currently approved antiviral treatment for COVID-19 is remdesivir, an inhibitor of viral genome replication. SARS-CoV-2 proliferation relies on the enzymatic activities of the non-structural proteins (nsp), which makes them interesting targets for the development of new antiviral treatments. With the aim to identify novel SARS-CoV-2 antivirals, we have purified the exoribonuclease/methyltransferase (nsp14) and its cofactor (nsp10) and developed biochemical assays compatible with highthroughput approaches to screen for exoribonuclease inhibitors. We have screened a library of over 5000 commercial compounds and identified patulin and aurintricarboxylic acid (ATA) as inhibitors of nsp14 exoribonuclease in vitro. We found that patulin and ATA inhibit replication of SARS-CoV-2 in a VERO E6 cell-culture model. These two new antiviral compounds will be valuable tools for further coronavirus research as well as potentially contributing to new therapeutic opportunities for COVID-19. [ABSTRACT FROM AUTHOR]

The coronavirus 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread around the world with unprecedented health and socio-economic effects for the global population. While different vaccines are now being made available, very few antiviral drugs have been approved. The main viral protease (nsp5) of SARS-CoV-2 provides an excellent target for antivirals, due to its essential and conserved function in the viral replication cycle. We have expressed, purified and developed assays for nsp5 protease activity. We screened the nsp5 protease against a custom chemical library of over 5000 characterised pharmaceuticals. We identified calpain inhibitor I and three different peptidyl fluoromethylketones (FMK) as inhibitors of nsp5 activity in vitro, with IC50 values in the low micromolar range. By altering the sequence of our peptidomimetic FMK inhibitors to better mimic the substrate sequence of nsp5, we generated an inhibitor with a subnanomolar IC50. Calpain inhibitor I inhibited viral infection in monkey-derived Vero E6 cells, with an EC50 in the low micromolar range. The most potent and commercially available peptidyl-FMK compound inhibited viral growth in Vero E6 cells to some extent, while our custom peptidyl FMK inhibitor offered a marked antiviral improvement. [ABSTRACT FROM AUTHOR]

The eukaryotic replisome is disassembled in each cell cycle, dependent upon ubiquitylation of the CMG helicase. Studies of Saccharomyces cerevisiae, Caenorhabditis elegans and Xenopus laevis have revealed surprising evolutionary diversity in the ubiquitin ligases that control CMG ubiquitylation, but regulated disassembly of the mammalian replisome has yet to be explored. Here, we describe a model system for studying the ubiquitylation and chromatin extraction of the mammalian CMG replisome, based on mouse embryonic stem cells. We show that the ubiquitin ligase CUL2LRR1 is required for ubiquitylation of the CMG‐MCM7 subunit during S‐phase, leading to disassembly by the p97 ATPase. Moreover, a second pathway of CMG disassembly is activated during mitosis, dependent upon the TRAIP ubiquitin ligase that is mutated in primordial dwarfism and mis‐regulated in various cancers. These findings indicate that replisome disassembly in diverse metazoa is regulated by a conserved pair of ubiquitin ligases, distinct from those present in other eukaryotes. SYNOPSIS: This study reports a model system based on mouse ESC to study the mammalian replisome. It shows that the ubiquitin ligases CUL2LRR1 and TRAIP control p97‐dependent replisome disassembly during DNA replication termination and mitosis, respectively. Mouse embryonic stem cells provide a rich source of the mammalian CMG helicase and associated replisome.CUL2LRR1 is required for p97‐dependent CMG helicase disassembly during DNA replication termination in mouse ES cells.The TRAIP ubiquitin ligase is required for a mitotic pathway of CMG helicase disassembly in mouse ES cells. [ABSTRACT FROM AUTHOR]